Clinical Outcome and 7-Day Virological Clearance in High-Risk Patients with Mild–Moderate COVID-19 Treated with Molnupiravir, Nirmatrelvir/Ritonavir, or …
F Bai, T Beringheli, V Vitaletti, A Santoro, F Molà… - Infectious Diseases and …, 2024 - Springer
Introduction We compared the effectiveness and virological clearance (VC) at day 7 (T7)
post-treatment with molnupiravir, nirmatrelvir/ritonavir, and remdesivir in SARS-CoV-2 …
post-treatment with molnupiravir, nirmatrelvir/ritonavir, and remdesivir in SARS-CoV-2 …
[HTML][HTML] Updated Bivalent COVID-19 Vaccines Reduce Risk of Hospitalization and Severe Outcomes in Adults: An Observational Cohort Study
N Mielke, S Johnson, C O'Sullivan… - Journal of Clinical …, 2024 - ncbi.nlm.nih.gov
Background This study evaluates the real-world effectiveness of updated bivalent
coronavirus disease 2019 (COVID-19) vaccines in adults, as the virus evolves and the need …
coronavirus disease 2019 (COVID-19) vaccines in adults, as the virus evolves and the need …